Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Acelrx Pharmaceutica (ACRX)

Acelrx Pharmaceutica (ACRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Acelrx Pharmaceutica 1850 Gateway Drive Suite 175 San Mateo CA 94404 USA

www.acelrx.com P: 650-216-3500

Description:

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California.

Key Statistics

Overview:

Market Capitalization, $K 14,579
Enterprise Value, $K 59
Shares Outstanding, K 16,952
Annual Sales, $ 1,770 K
Annual Net Income, $ 47,760 K
Last Quarter Sales, $ 120 K
Last Quarter Net Income, $ -1,360 K
EBIT, $ -20,040 K
EBITDA, $ -18,390 K
60-Month Beta 0.52
% of Insider Shareholders 3.00%
% of Institutional Shareholders 19.79%
Float, K 16,443
% Float 97.00%
Short Volume Ratio 0.41

Growth:

1-Year Return -60.55%
3-Year Return -97.93%
5-Year Return -98.29%
5-Year Revenue Growth -77.88%
5-Year Earnings Growth 123.55%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.08 on 11/08/23
Latest Earnings Date N/A
Earnings Per Share ttm -1.49
EPS Growth vs. Prev Qtr 80.49%
EPS Growth vs. Prev Year 91.49%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 10/26/22

ACRX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -81.54%
Return-on-Assets % -46.02%
Profit Margin % 2,698.31%
Debt/Equity 0.00
Price/Sales 4.64
Price/Cash Flow N/A
Price/Book 0.77
Book Value/Share 1.12
Interest Coverage 2,389.50
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar